- Home
- FORA vs VRCA Comparison
FORA vs VRCA Comparison
Compare FORA & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- VRCA
- Stock Information
- Founded
- FORA 2014
- VRCA 2013
- Country
- FORA United States
- VRCA United States
- Employees
- FORA N/A
- VRCA N/A
- Industry
- FORA Computer Software: Prepackaged Software
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- VRCA Health Care
- Exchange
- FORA Nasdaq
- VRCA Nasdaq
- Market Cap
- FORA 59.9M
- VRCA 52.1M
- IPO Year
- FORA N/A
- VRCA 2018
- Fundamental
- Price
- FORA $1.92
- VRCA $5.64
- Analyst Decision
- FORA Strong Buy
- VRCA Hold
- Analyst Count
- FORA 1
- VRCA 5
- Target Price
- FORA $5.00
- VRCA $6.00
- AVG Volume (30 Days)
- FORA 13.3K
- VRCA 56.5K
- Earning Date
- FORA 08-13-2025
- VRCA 08-13-2025
- Dividend Yield
- FORA N/A
- VRCA N/A
- EPS Growth
- FORA N/A
- VRCA N/A
- EPS
- FORA N/A
- VRCA N/A
- Revenue
- FORA $22,332,001.00
- VRCA $7,179,000.00
- Revenue This Year
- FORA $46.25
- VRCA $165.25
- Revenue Next Year
- FORA $11.30
- VRCA $80.06
- P/E Ratio
- FORA N/A
- VRCA N/A
- Revenue Growth
- FORA 5.22
- VRCA N/A
- 52 Week Low
- FORA $1.85
- VRCA $3.82
- 52 Week High
- FORA $4.03
- VRCA $66.40
- Technical
- Relative Strength Index (RSI)
- FORA 43.99
- VRCA 36.00
- Support Level
- FORA $1.92
- VRCA $5.86
- Resistance Level
- FORA $2.06
- VRCA $7.13
- Average True Range (ATR)
- FORA 0.07
- VRCA 0.77
- MACD
- FORA -0.00
- VRCA -0.31
- Stochastic Oscillator
- FORA 4.76
- VRCA 9.70
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.